iLIVER最新文献

{"title":"Short-term effects of modified ultrasonography in laparoscopic anatomical hepatectomy for hepatocellular carcinoma","authors":"Xun Wang ,&nbsp;Xuan Meng ,&nbsp;Liming Wang,&nbsp;Peng Wang,&nbsp;Zhihao Wang,&nbsp;Weiqi Rong,&nbsp;Zhiyu Lu,&nbsp;Hongguang Wang","doi":"10.1016/j.iliver.2024.100106","DOIUrl":"10.1016/j.iliver.2024.100106","url":null,"abstract":"<div><h3>Background and aims</h3><p>Laparoscopic hepatectomy is challenging, and ultrasound guidance is an effective aid but lacks standardization. This study aimed to evaluate a modified approach for laparoscopic ultrasonography to enhance surgical outcomes.</p></div><div><h3>Methods</h3><p>Between January 2020 and August 2023, 122 patients who underwent real-time ultrasound-guided laparoscopic anatomical hepatectomy for hepatocellular carcinoma were enrolled and divided into modified and traditional ultrasonography groups. The modified ultrasound application comprised intraoperative protocol-based laparoscopic ultrasonography comprising application scenarios; standardized positions for the surgeon, trocar, and probe; and the resulting standardized sections for various laparoscopic liver resections. Clinical characteristics and perioperative outcomes were compared between the two groups. Subgroup analysis was performed and comprised techniques for modified duct structure identification and portal vein branch puncture; both techniques were used in fluorescence probe-mounted laparoscopic liver resection using negative and positive staining procedures, respectively.</p></div><div><h3>Results</h3><p>The traditional and modified groups comprised 64 and 58 patients, respectively. The patients’ background characteristics were not significantly different between the groups. Surgical duration (283.4 min vs. 225.1 min; <em>p</em> &lt; 0.001), Pringle maneuver duration (47.4 min vs. 39.5 min; <em>p</em> = 0.014), bleeding volume (258.6 mL vs. 174.8 mL; <em>p</em> = 0.005), overall complication rate (31.3% vs. 15.5%; <em>p</em> = 0.041), and postoperative stay were significantly greater in the traditional vs. modified ultrasonography groups, respectively. The modified method positively affected the number of punctures, success rate of staining, intraoperative bleeding volume, and operation duration.</p></div><div><h3>Conclusions</h3><p>Modified ultrasonography improves the safety and effectiveness of laparoscopic hepatectomy. Ultrasonography is pivotal, especially in fluorescence probe-assisted laparoscopic liver resection.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000318/pdfft?md5=be0303c5aa9e5b1f82a1533c9b8ebe58&pid=1-s2.0-S2772947824000318-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141708607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCL16 inhibits tumor proliferation and metastasis in HCC by impacting CK19 phenotype","authors":"Huigang Li ,&nbsp;Jianyong Zhuo ,&nbsp;Peiru Zhang ,&nbsp;Jinyan Chen ,&nbsp;Zuyuan Lin ,&nbsp;Xudong Yang ,&nbsp;Ruijie Zhao ,&nbsp;Chenghao Cao ,&nbsp;Wei Shen ,&nbsp;Chiyu He ,&nbsp;Hao Chen ,&nbsp;Ting Lv ,&nbsp;Xuyong Wei ,&nbsp;Shusen Zheng ,&nbsp;Xiao Xu ,&nbsp;Di Lu","doi":"10.1016/j.iliver.2024.100096","DOIUrl":"10.1016/j.iliver.2024.100096","url":null,"abstract":"<div><h3>Background and aims</h3><p>Cytokeratin 19–positive (CK19+) hepatocellular carcinoma (HCC) is an aggressive subtype with poor outcomes. The initiation and development of CK19+ HCC in the background of liver cirrhosis remains unclear. This study investigated the role of the cirrhosis-related gene C–C motif chemokine ligand 16 (CCL16) in the development of CK19+ HCC.</p></div><div><h3>Methods</h3><p>Datasets from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) were analyzed to screen and validate the genes associated with CK19+ HCC. A total of 102 HCC patients were included for tissue microarray analysis. Gain-of-function experiments were conducted to investigate the biological functions of CCL16. CIBERSORT was used to investigate the correlation of CCL16 and immune infiltration.</p></div><div><h3>Results</h3><p>GEO dataset analysis showed that CK19+ HCC had lower expression of CCL16. In both TCGA dataset and our HCC cohort, CCL16 expression was negatively correlated with CK19 expression (<em>P</em> ​&lt; ​0.05) and its expression was higher in para-tumor than tumor tissues (<em>P</em> ​&lt; ​0.001). Moreover, low CCL16 expression was related to advanced stage and poor overall survival (<em>P</em> ​&lt; ​0.05). CCL16 overexpression downregulated CK19 expression and impacted the sphere formation ability of HCC cells. Overexpression of CCL16 inhibited the cell proliferation, migration, and invasion of HCC cell lines. Immune analysis showed HCC with high CCL16 expression had more infiltration of mast cells. HCC patients with both low CCL16 expression and low mast cells had the worst prognosis (<em>P</em> ​&lt; ​0.001).</p></div><div><h3>Conclusion</h3><p>Our data indicated that CCL16 downregulated the expression of CK19 and inhibited the malignant phenotype of HCC.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100096"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000215/pdfft?md5=b5bdf50abc10a7dd4931f45f1e281ee8&pid=1-s2.0-S2772947824000215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141133699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome is associated with significant hepatic fibrosis and steatosis in patients with nonalcoholic steatohepatitis","authors":"Qian-Qian Li ,&nbsp;Yu-Ting Xiong ,&nbsp;Danni Wang ,&nbsp;Ke-Xin Wang ,&nbsp;Chang Guo ,&nbsp;Yi-Ming Fu ,&nbsp;Xiao-Xia Niu ,&nbsp;Chun-Yan Wang ,&nbsp;Jian-Jun Wang ,&nbsp;Dong Ji ,&nbsp;Zhi-Fang Bai","doi":"10.1016/j.iliver.2024.100094","DOIUrl":"10.1016/j.iliver.2024.100094","url":null,"abstract":"<div><h3>Background and aims</h3><p>Nonalcoholic steatohepatitis (NASH), an inflammatory form of non-alcoholic fatty liver disease, can progress to advanced liver fibrosis, cirrhosis, and liver cancer. Metabolic syndrome (MetS) parallels the prevalence of non-alcoholic fatty liver disease/NASH and increases patients’ risk of advanced liver disease. This study aimed to determine whether MetS was associated with the histological progression of NASH.</p></div><div><h3>Methods</h3><p>Patients with liver biopsy-proven NASH were retrospectively screened and categorized into two groups for each histological feature: with (&lt;2 points) or without (≥2 points) significant hepatic steatosis/inflammation/fibrosis. Multivariable logistic regression was used to explore the association between MetS and histological features.</p></div><div><h3>Results</h3><p>In total, 386 patients with a median age of 33.0 years were enrolled; among them, 35.2% were female, and 41.2% had MetS. The proportion of significant hepatic fibrosis and steatosis in those with MetS was significantly higher than in those without MetS (<em>p</em> &lt; 0.05). Multivariable logistic regression analyses showed that MetS remained significantly associated with significant hepatic fibrosis (adjusted odds ratio: 1.852, 95% confidence interval: 1.042–3.292, <em>p</em> = 0.036), and severe hepatic steatosis (adjusted odds ratio: 2.008, 95% confidence interval: 1.030–3.914, <em>p</em> = 0.041).</p></div><div><h3>Conclusion</h3><p>MetS was associated with significant hepatic fibrosis and steatosis in patients with NASH. Our results suggest that NASH patients with MetS should be closely monitored and given targeted intervention and treatment, which may help to prevent disease progression and mitigate the growing burden of NASH.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000197/pdfft?md5=ea4ea081a890891e2b017963d6e2344a&pid=1-s2.0-S2772947824000197-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140768689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury","authors":"Yu-Ting Xiong ,&nbsp;Jian-Fei Wang ,&nbsp;Le Li ,&nbsp;Zhi-Fang Bai ,&nbsp;Yan Liu ,&nbsp;Ang Huang ,&nbsp;Ke-Xin Wang ,&nbsp;Yiming Fu ,&nbsp;Wucai Yang ,&nbsp;Chang Guo ,&nbsp;Mengwen He ,&nbsp;Wen-Chang Wang ,&nbsp;Chun-Yan Wang ,&nbsp;Dong Ji","doi":"10.1016/j.iliver.2024.100095","DOIUrl":"10.1016/j.iliver.2024.100095","url":null,"abstract":"<div><h3>Background</h3><p>Currently, research on biopsy-proven acute drug-induced liver injury (DILI) remains limited. This study aimed to identify clinical characteristics and risk factors for significant hepatic inflammation in patients with acute DILI.</p></div><div><h3>Methods</h3><p>An ambispective cohort study was conducted on biopsy-proven acute DILI patients admitted to our hospital from 2012 to 2018. Using the Scheuer scoring system, patients were categorized into G0-2 or G3-4 groups and followed up for 12 months after first admission. Clinical characteristics and outcomes were retrieved from medical records.</p></div><div><h3>Results</h3><p>The median age of the 157 enrolled patients (65.6% female) was 40.4 (interquartile range (IQR), 31.9–49.1) years. The median latency and length of hospitalization were 30.0 (IQR, 5.0–60.0) and 18.0 (IQR, 12.0–26.0) days. The proportions of patients in the G0-2 and G3-4 groups were 54.8% and 45.2%, respectively. Logistic regression analysis revealed that females (odds ratio (OR): 2.623, 95% confidence interval (CI): 1.169–5.887, <em>p</em> = 0.019), higher body mass index (OR: 1.168, 95% CI: 1.029–1.325, <em>p</em> = 0.016), higher total bilirubin (OR: 1.004, 95% CI: 1.000–1.007, <em>p</em> = 0.047), and lower prothrombin activity (OR: 0.976, 95% CI: 0,957–0.995, <em>p</em> = 0.013) were associated with significant hepatic inflammation. The predominance of the hepatocellular injury pattern (60.5%) at admission transformed into a predominance of the cholestatic pattern (60.5%) at discharge. During follow-up, 23 patients (14.6%) developed chronic DILI, with nine patients (5.7%) progressing to cirrhosis. Moreover, 15 female patients (9.6%) developed autoimmunity (3cases in the G0-2 group vs 12 cases in the G3-4 group, <em>p</em> &lt; 0.05).</p></div><div><h3>Conclusions</h3><p>Acute DILI patients with high-risk factors were more likely to develop significant hepatic inflammation, and females with significant inflammation were at a higher risk of developing autoimmunity during follow-up.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100095"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000203/pdfft?md5=645003e67eda5eb4ceb14fc881bc62ed&pid=1-s2.0-S2772947824000203-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141038690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease","authors":"Wei Ouyang ,&nbsp;Ming-Da Wang ,&nbsp;Ming-Cheng Guan ,&nbsp;Yong-Kang Diao ,&nbsp;Li-Yang Sun ,&nbsp;Nan-Ya Wang ,&nbsp;Feng Shen ,&nbsp;Hong Zhu ,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100098","DOIUrl":"10.1016/j.iliver.2024.100098","url":null,"abstract":"<div><h3>Background and aims</h3><p>The ASAP and GALAD scores are widely used diagnostic models for detecting hepatocellular carcinoma (HCC), incorporating factors such as sex, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II), and lens culinaris agglutinin-reactive fraction of AFP (AFP-L3%). This study compares the diagnostic efficacy of the ASAP and GALAD scores in the early detection of HCC in patients with non-alcoholic fatty liver disease (NAFLD).</p></div><div><h3>Methods</h3><p>NAFLD patients with and without HCC were recruited from 12 Chinese tertiary hospitals. Serum levels of AFP, PIVKA-II, and AFP-L3% were measured. The diagnostic accuracy of individual biomarkers, the ASAP score, and the GALAD score in detecting NAFLD-HCC at various stages was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC) values.</p></div><div><h3>Results</h3><p>In a cohort of 147 NAFLD-HCC cases and 460 NAFLD controls, both the ASAP and GALAD scores outperformed individual biomarkers in detecting NAFLD-HCC. The ASAP score demonstrated a high AUC of 0.910 (sensitivity: 80.3%, specificity: 92.8%) for identifying NAFLD-HCC at all stages, surpassing AFP (AUC: 0.716, <em>P</em> &lt; 0.001), PIVKA-II (AUC: 0.849, <em>P</em> &lt; 0.001), AFP-L3% (AUC: 0.663, <em>P</em> &lt; 0.001), and the GALAD score (AUC: 0.882, <em>P</em> = 0.014). Comparable results were observed for early-stage NAFLD-HCC and for detecting HCC in NAFLD patients with or without cirrhosis.</p></div><div><h3>Conclusion</h3><p>The ASAP score, which excludes the AFP-L3% indicator, demonstrated superior performance in differentiating NAFLD-HCC compared to the GALAD score, suggesting its potential for early screening of HCC in NAFLD patients.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100098"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000239/pdfft?md5=3f1832536c1a71cc8de9d107a8cce2c7&pid=1-s2.0-S2772947824000239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141139101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver transplantation and immune tolerance: Setting the stage for optimal post-transplant status","authors":"Jiaying Cao,&nbsp;Qi Ling","doi":"10.1016/j.iliver.2024.100097","DOIUrl":"10.1016/j.iliver.2024.100097","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100097"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000227/pdfft?md5=88237d48481d600184c150e90112c29a&pid=1-s2.0-S2772947824000227-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141138982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of cessation of nucleoside/nucleotide analogues in Chinese patients with HBeAg-negative chronic hepatitis B","authors":"Fengyi Li ,&nbsp;Yadong Zhang ,&nbsp;Chao Liu ,&nbsp;Juan Li ,&nbsp;Dali Zhang ,&nbsp;Yinjie Gao","doi":"10.1016/j.iliver.2024.100093","DOIUrl":"10.1016/j.iliver.2024.100093","url":null,"abstract":"<div><h3>Background</h3><p>Cessation of nucleoside/nucleotide analogue (Nuc) therapy in patients with HBeAg-negative chronic hepatitis B (CHB) remains controversial.</p></div><div><h3>Methods</h3><p>In this prospective, single-center cohort study, we recruited 45 patients with HBeAg-negative CHB from The Fifth Medical Center of Chinese People's Liberation Army General Hospital in mainland China. Patients were classified into a Nuc cessation group (<em>n</em> = 27) and Nuc continuation group (<em>n</em> = 18) and followed-up for 36 months. Nuc were stopped after being inactive for at least 4 years (normal alanine aminotransferase (ALT), undetectable hepatitis B virus (HBV) DNA), with liver fibrosis ≤ Stage1 (S1) and inflammation ≤ Grade (G1).</p></div><div><h3>Results</h3><p>Within 3 years of follow-up, 51.9% patients with Nuc cessation had virological relapse and 14.8% had ALT elevation, while all patients with Nuc continuation had undetectable HBV DNA and normal ALT. The rate of HBsAg loss after Nuc cessation was 22.2% compared with no seroconversion in patients with Nuc continuation. The hepatitis flare rate was 11.1% and there were no cases of hepatic decompensation after Nuc cessation. End of treatment (EOT) HBsAg, HBV RNA, and decline in HBV core-related antigen (HBcrAg) rate were predictive markers for HBsAg seroconversion at 6 months post-Nuc cessation.</p></div><div><h3>Conclusions</h3><p>This study showed favorable HBsAg loss and low hepatitis flare rates after Nuc cessation. EOT HBsAg, HBV RNA, and decline in HBcrAg rate were predictive markers for HBsAg seroconversion at 6 months post-Nuc cessation.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100093"},"PeriodicalIF":0.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000185/pdfft?md5=281d1e196ead862d400d47395ba25156&pid=1-s2.0-S2772947824000185-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140398463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma: A real-world clinical study","authors":"Zhongchao Li,&nbsp;Jingtao Zhong,&nbsp;Chengsheng Zhang,&nbsp;Bo Zhang,&nbsp;Xuetao Shi,&nbsp;Lei Li","doi":"10.1016/j.iliver.2024.100092","DOIUrl":"10.1016/j.iliver.2024.100092","url":null,"abstract":"<div><h3>Background and aims</h3><p>Hepatocellular carcinoma (HCC) is a prevalent and deadly disease with limited treatment options. Regorafenib, a tyrosine kinase inhibitor, has shown promise in HCC treatment but faces limitations as a monotherapy. Combining regorafenib with PD-1 inhibitor may improve efficacy and survival outcomes for patients. This retrospective analysis was conducted to explore its efficacy and safety, providing reference experience for better application of this combination therapy.</p></div><div><h3>Methods</h3><p>This retrospective single-center study evaluated the efficacy and safety of combining regorafenib with PD-1 blockade for patients with HCC. Efficacy was evaluated according to the RECIST 1.1 evaluation criteria. Safety was assessed using CTCAE 4.0. Data was analyzed to compare survival status in different subgroups.</p></div><div><h3>Results</h3><p>Generally, there were 76 patients with HCC elected to receive the regorafenib plus PD-1 blockade treatment during the study period. The objective response rate was 21.1% (<em>n</em> = 16), and the disease control rate was 56.6% (<em>n</em> = 43). Median progression-free survival (PFS) was 6.8 months, and median overall survival had not yet been reached. All patients suffered of at least 1 adverse event. Grade ≥3 adverse events occurred in 31.6% of patients (<em>n</em> = 24), with the most common being hand-foot syndrome, decreased appetite, and abdominal distension. Subgroup analyses showed no significant differences in PFS based on cirrhosis status or previous treatment lines.</p></div><div><h3>Conclusions</h3><p>With manageable safety, regorafenib combined PD-1 inhibitor could bring survival benefits for advanced HCC who have received systemic treatment. Further, the Cox analysis showed that HBV infection, metastasis, etc. did not have significant effects on the survival benefits.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000173/pdfft?md5=714108c0991fc3608cf1d3f3d027572c&pid=1-s2.0-S2772947824000173-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140405142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the future of liver disease research: A roadmap for iLIVER","authors":"Lei Cai,&nbsp;Ming-Da Wang,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100084","DOIUrl":"https://doi.org/10.1016/j.iliver.2024.100084","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100084"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000094/pdfft?md5=118dead8c509dfd177b9b6c0e5ee1c03&pid=1-s2.0-S2772947824000094-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140096204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for esophagogastric variceal-related poor outcomes in primary biliary cholangitis: A prospective cohort study","authors":"Lin Han ,&nbsp;Huan Xie ,&nbsp;Xue-Mei Ma ,&nbsp;Xiao-Long Lu ,&nbsp;Jun Zhao ,&nbsp;Qing-Sheng Liang ,&nbsp;Zheng-Sheng Zou ,&nbsp;Jing-Feng Bi ,&nbsp;Bo Jin ,&nbsp;Ying Sun","doi":"10.1016/j.iliver.2024.100081","DOIUrl":"10.1016/j.iliver.2024.100081","url":null,"abstract":"<div><h3>Background and aims</h3><p>Esophagogastric varices (EGV) are common complications of primary biliary cholangitis (PBC). We examined the risk factors for variceal bleeding-related liver transplantation (LT) or death.</p></div><div><h3>Methods</h3><p>This prospective observational cohort study involved PBC in our hospital from 1 January 2005 to 1 January 2020. The clinical endpoints were variceal bleeding-related LT and death. Survival analysis was performed using the Kaplan–Meier estimate, cox regression analysis was performed to investigate risk factors.</p></div><div><h3>Results</h3><p>PBC with EGV had significantly shorter survival than those without (<em>p</em> = 0.002). Endoscopic prophylaxis significantly improved poor outcomes in PBC with EGV (<em>p</em> <em>&lt;</em> 0.001). Risk factors in patients with EGV included: cholinesterase (CHE) of &lt;1.0 × upper limit of normal (ULN), international normalized ratio (INR) of &gt;1.2 × ULN at baseline, total bilirubin of &gt;1.2 × ULN, aspartate aminotransferase (AST) of &gt;2.3 × ULN after 1 year of ursodeoxycholic acid (UDCA) treatment, non-biochemical responders according to the Paris criteria, and no history of endoscopic therapy. In PBC without EGV, risk factors included AST of &gt;2.3 × ULN, INR of &gt;1.2 × ULN at baseline, CHE of &lt;1.0 × ULN after 1 year of UDCA treatment, and GLOBE score of &gt;1.125.</p></div><div><h3>Conclusion</h3><p>This study provides evidence that AST, INR and CHE are major risk factors for variceal bleeding-related poor outcomes in PBC. For PBC with EGV, a good biochemical response to UDCA and endoscopic prophylaxis may improve survival. These findings can aid for guiding initial PBC risk stratification and screening endoscopy in patients without EGV.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100081"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000069/pdfft?md5=b86f241c6c5e865ce844c195f7d4042e&pid=1-s2.0-S2772947824000069-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139813751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}